Why carry out this study?

Vitiligo is a severely undertreated disease with only one approved treatment for repigmentation (ruxolitinib); other treatment options have limitations, such as poor efficacy and side effects associated with long-term use

There is an absence of evidence on treatment utilization or treatment patterns for patients with vitiligo

What was learned from the study?

In this real-world study, a high proportion of patients newly diagnosed with vitiligo did not receive any treatment

Among those receiving treatment, corticosteroids (topical and oral) and topical calcineurin inhibitors were the most used first-line treatment but varied by age

Patients were unlikely to switch or use a combination of treatments within the first year of vitiligo diagnosis